Experimental Hematology and Oncology

OCT 22, 2026 · JOURNAL ARTICLE

Oncogenic RAS as an adaptive signaling ecosystem: context-dependent vulnerabilities and resistance-informed therapeutic design

Experimental Hematology and Oncology

Direct RAS targeting has progressed from pharmacologic proof of concept to routine treatment for selected KRAS G12C-mutant cancers. KRAS G12C inhibitors and KRAS G12C-EGFR combinat

OCT 22, 2026 · JOURNAL ARTICLE

Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation

Experimental Hematology and Oncology

Cancer remains a formidable challenge in global oncology, with conventional treatments often failing to achieve durable responses in advanced stages. Adoptive cell therapy (ACT), d

OCT 20, 2026 · JOURNAL ARTICLE

Cobimetinib impairs tumor survival and immune escape by altering my-CAFs in BRAFV600E-mutated anaplastic thyroid carcinoma

Experimental Hematology and Oncology

Abstract Anaplastic thyroid carcinoma is one of the most aggressive thyroid cancers characterized by rapid progression and high resistance to conventional therapies. Although mutat

OCT 16, 2026 · JOURNAL ARTICLE

Intratumoral microbiota in cancer immunotherapy: metabolic-epigenetic crosstalk and engineered bacterial therapeutics

Experimental Hematology and Oncology

The intratumoral microbiome critically influences immunotherapy efficacy by modulating the host immune microenvironment and epigenetic landscape through its metabolites. Microbial

AUG 14, 2026 · JOURNAL ARTICLE

Targeting SLC6A14-mediated nutrient competition reverses an immunosuppressive metabolic niche in pancreatic cancer

Experimental Hematology and Oncology

Preclinical mechanistic study with in vitro and in vivo experiments identifying a putative target and lead inhibitor, lacking clinical efficacy or safety data in humans.